scholarly journals PD ‐1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma

2020 ◽  
Author(s):  
Tahlia Scheinberg ◽  
Anna Lomax ◽  
Martin Tattersall ◽  
David Thomas ◽  
Geoff McCowage ◽  
...  
Keyword(s):  
Young Adult ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Adult Patients ◽  
Adolescent And Young Adult

scholarly journals Soft tissue sarcoma in adolescent and young adult patients: a retrospective study using a nationwide bone and soft tissue tumor registry in Japan

2021 ◽  
Author(s):  
Takashi Fukushima ◽  
Koichi Ogura ◽  
Toru Akiyama ◽  
Katsushi Takeshita ◽  
Akira Kawai
Keyword(s):  
Young Adult ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Peripheral Nerve ◽  
Soft Tissue Tumor ◽  
Cancer Survival ◽  
Age Groups ◽  
Adult Patients ◽  
Adolescent And Young Adult ◽  
Peripheral Nerve Sheath Tumor

Abstract Objective The relationship between the adolescent and young adult age groups and poor overall survival in soft tissue sarcoma and the risk factors for poor outcomes in adolescent and young adult patients with soft tissue sarcoma were analyzed. Methods The medical records of 7759 Japanese patients diagnosed with soft tissue sarcoma from 2006–13 were accessed from the Bone and Soft Tissue Tumor registry. The epidemiological features of adolescent and young adult patients were compared with those of other age groups. The cancer survival rates were calculated using the Kaplan-Meier method. The prognostic factors for cancer survival were analyzed with the Cox proportional hazards models. The primary endpoint for prognosis was tumor-related death. Results There were 210 children, 1467 adolescent and young adults, 2771 adults and 3311 elderly among the 7759 patients identified with soft tissue sarcoma. Compared with other age groups, the proportions of myxoid/round cell liposarcoma, synovial sarcoma, malignant peripheral nerve sheath tumor, primitive neuroectodermal tumor and rhabdomyosarcoma in adolescent and young adult patients were the highest, but none was significantly more prevalent in adolescent and young adult patients. On multivariate analysis, age was not a prognostic factor for poor cancer survival among adolescent and young adult patients with soft tissue sarcoma. The cancer survival rates of adolescent and young adult patients with malignant peripheral nerve sheath tumor were poorer than those of the other age groups; however, adolescent and young adult age was not a prognostic factor on multivariate analysis in malignant peripheral nerve sheath tumor patients. Conclusions Our study is the first to investigate soft tissue sarcoma in adolescent and young adult patients using the nationwide Bone and Soft Tissue Tumor registry. Adolescent and young adult age is not a prognostic factor for poor cancer survival among those with soft tissue sarcoma in Japan.

scholarly journals Nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) in pediatric and young adult patients: Results from a prospective study using limited-margin radiotherapy

Cancer ◽  
2017 ◽  
Vol 123 (22) ◽  
pp. 4419-4429 ◽  
Author(s):  
Christopher L. Tinkle ◽  
Israel Fernandez-Pineda ◽  
April Sykes ◽  
Zhaohua Lu ◽  
Chia-ho Hua ◽  
...  
Keyword(s):  
Young Adult ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Prospective Study ◽  
Adult Patients ◽  
A Prospective Study

scholarly journals PD-1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 3060-3060 ◽  
Author(s):  
Tahlia Scheinberg ◽  
Anna Lomax ◽  
Martin HN Tattersall ◽  
David Morgan Thomas ◽  
Geoffrey Brian McCowage ◽  
...  
Keyword(s):  
Young Adult ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Soft Part ◽  
Initial Response ◽  
Clear Cell Sarcoma ◽  
Median Number ◽  
Adolescent And Young Adult ◽  
Improved Outcomes ◽  
Ecog Ps

3060 Background: Sarcomas represent 10–15% of cancers in adolescent and young adult (AYA) patients, and survival for those with metastatic disease or after relapse is poor. Immunotherapy with checkpoint inhibition has improved outcomes in multiple tumour types, but there are limited data on the efficacy of immunotherapy in advanced sarcomas, particularly within the AYA population. Methods: We retrospectively reviewed AYA patients with advanced bone and soft tissue sarcoma who received self-funded pembrolizumab at Chris O’Brien Lifehouse and Children’s Hospital Westmead. Initial response was evaluated after cycle three or four using RECIST v1.1 criteria. Results: Fourteen AYA patients with sarcoma received pembrolizumab 2mg/kg IV every 3 weeks from May 2015 to December 2016. Median age was 24 (14 – 35), male to female was 7:7, ECOG PS was 0 – 1 in 6 patients, 2 in 6 patients and 3 – 4 in 2 patients. Malignancy type included three patients with osteosarcoma (OS), five patients with Ewing sarcoma (ES), two patients with synovial sarcoma (SS), two patients with alveolar soft part sarcoma (ASPS), and one patient with each of embryonal rhabdomyosarcoma (RMS) and clear cell sarcoma (CCS). The median number of pembrolizumab doses was four (range 1 – 16), with one patient still receiving treatment at the time of last follow up. Treatment was generally very well tolerated with no G3-4 toxicity. One patient with ES had an excellent, sustained response; of the two patients with ASPS one had a radiological partial response with an excellent clinical response and one patient achieved stable disease. Three patients (two ES, one RMS) died of disease prior to first scheduled assessment and thus their response was not evaluable. The remaining 8 patients had progressive disease. Conclusions: Our data suggest further evaluation of the role of pembrolizumab in AYA patients with advanced sarcoma is warranted.

scholarly journals Conditional survival of pediatric, adolescent, and young adult soft tissue sarcoma and bone tumor patients

2017 ◽  
Vol 50 ◽  
pp. 150-157 ◽  
Author(s):  
Judy Y. Ou ◽  
Holly Spraker-Perlman ◽  
Andrew C. Dietz ◽  
Rochelle R. Smits-Seemann ◽  
Sapna Kaul ◽  
...  
Keyword(s):  
Young Adult ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Bone Tumor ◽  
Adolescent And Young Adult ◽  
Conditional Survival ◽  
Tumor Patients
Sign in / Sign up

Export Citation Format

Share Document